CAR-T: What Is Next?
2023 · Cancers · 201 citations
https://doi.org/10.3390/cancers15030663
Y
Yasser Mostafa Kamel
Cairo University(EG)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
59
Papers
1.2K
Citations
13
h-index
16
i10-index
Yasser Mostafa Kamel is an academic researcher from Cairo University. The author has contributed to research in topics: Acute Myeloid Leukemia Research & Chronic Lymphocytic Leukemia Research & Chronic Myeloid Leukemia Treatments. The author has an h-index of 13, co-authored 51 publications.
ORCID: 0000-0001-7001-0122Papers by this author
worksExtended pharmacological thromboprophylaxis and clinically relevant venous thromboembolism after major abdominal and pelvic surgery: international, prospective, propensity score-weighted cohort study
2025 · British journal of surgery · 2 citations
https://doi.org/10.1093/bjs/znaf005
Extended pharmacological thromboprophylaxis and clinically relevant venous thromboembolism after major abdominal and pelvic surgery: international, prospective, propensity score-weighted cohort study
2025 · British journal of surgery · 2 citations
https://doi.org/10.1093/bjs/znaf005
AML-202 QuANTUM-First: Efficacy by Age in Newly Diagnosed (nd) Patients With FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication–Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML)
2024 · Clinical Lymphoma Myeloma & Leukemia · 1 citations
https://doi.org/10.1016/s2152-2650(24)01170-4
AML-197 QuANTUM-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication (FLT3-ITD)–Specific Measurable Residual Disease (MRD) Clearance Assessed Through Induction and Consolidation Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (ND) FLT3-ITD+ AML Patients
2024 · Clinical Lymphoma Myeloma & Leukemia · 0 citations
https://doi.org/10.1016/s2152-2650(24)01169-8
QuANTUM-First: Efficacy by Age in Newly Diagnosed (nd) Patients With FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication-Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML)
2024 · Clinical Lymphoma Myeloma & Leukemia · 0 citations
https://doi.org/10.1016/s2152-2650(24)00480-4
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat